Encorafenib
Back to searchMolecule Structure
Scientific Name
Encorafenib
Description of the Drug
Encorafenib is a kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11718
http://www.drugbank.ca/drugs/DB11718
Brand Name(s)
Braftovi
Company Owner(s)
Array Biopharma Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Serine/threonine-protein kinase B-raf | SINGLE PROTEIN | INHIBITOR | CHEMBL5145 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL8228295 | |
| PharmGKB | PA166179872 | |
| Human Metabolome Database | HMDB0304887 | |
| DrugBank | DB11718 | |
| PubChem: Thomson Pharma | 113916820 | |
| PubChem | 50922675 | |
| Nikkaji | J3.371.287A | |
| BindingDB | 221688 | |
| EPA CompTox Dashboard | DTXSID00155347 | |
| DrugCentral | 5289 | |
| ChemicalBook | CB42668617 | |
| Guide to Pharmacology | 7908 | |
| rxnorm | ENCORAFENIB | BRAFTOVI |
| ZINC | ZINC000068249103 |
